Monitoring of TCR clonotype and diversity of CD8+PD-1+ T-cells in lung cancer patients treated with PD-1 blockade: A Biomarker Study.

Monitoring of TCR clonotype and diversity of CD8+PD-1+ T-cells in lung cancer patients treated with PD-1 blockade: A Biomarker Study. - TCR clonotype and diversity of CD8+PD-1+ T-cells in lung cancer patients treated with PD-1 blockade

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043063

Enrollment

100

Registered

2021-01-20

Start date

2019-12-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment naive non-small cell lung cancer patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Treatment naive Advanced NSCLC patients. 2) Treatment with pembrolizumab. 3) Written Informed consent

Exclusion criteria

Exclusion criteria: 1) Patients judged as inappropriate for the study by the investigator

Design outcomes

Primary

Measure	Time frame
To evaluate the association between the efficacy of pembrolizumab and TCR clonotype on CD8+PD-1+ T-cells	—

Countries

Japan

Contacts

Public ContactTatsuya Yoshida

National Cancer Center Hospital Department of thoracic oncology

tatyoshi@ncc.go.jp03-3542-2511

Outcome results